Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
53.99%
Operating Margin
24.12%
Net Margin
16.58%
Efficiency Metrics
Revenue per Expense Ratio
1.32
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
31.59%
Income Tax Rate
17.65%
EPS
6.1200000000
Balance Sheet Analysis
Current Ratio
0.89
Cash Ratio
0.52
Working Capital
$-67.01M
Debt to Equity
2.14
Debt to Assets
57.12%
Equity Ratio
26.74%
Cash Flow Analysis
Operating Cash Flow Ratio
24.46%
Free Cash Flow Ratio
14.46%
CapEx to Revenue
10.00%
Dividends Paid
$63.61M
Stock Buybacks
$412.66M
Total Shareholder Returns
$476.26M
Cash Position Change
4.36%
Key Takeaways (2023 FY)
Increased dividend payments by 41.93%
Increased R&D investment by 547.00%
Detailed Growth Metrics
Core Performance
Revenue
5.15%
Net Income
-3.03%
EPS
4.26%
Operating Income
-8.09%
Operational Efficiency
R&D Expenses
547.00%
SG&A Expenses
3.68%
Operating Cash Flow
-6.31%
Free Cash Flow
-23.54%
Balance Sheet Health
Assets
-0.60%
Debt
-4.39%
Book Value per Share
17.83%
Inventory
-6.68%
Shareholder Returns
Dividends per Share
41.93%
Shares Outstanding
-6.94%
Long Term Trends
3Y Revenue/Share
92.25%
5Y Revenue/Share
60.69%
3Y Dividend/Share
812.67%
5Y Dividend/Share
190.41%